Evidence-based Research
Efficacy and safety of ixazomib in patients with relapsed/refractory multiple myeloma in the real world: meta-analysis of single proportions
Li Yun, Li Bingsheng, Yuan Zhen, Liu Bin, Li Yixiu, Ao Jian'gen
Published 2023-10-28
Cite as ADRJ, 2023, 25(10): 614-621. DOI: 10.3760/cma.j.cn114015-20221227-01184
Abstract
ObjectiveTo systematically evaluate the efficacy and safety of ixazomib in patients with relapsed or refractory multiple myeloma (RRMM) in the real world.
MethodsRelevant databases at home and abroad were searched (up to April 2022), and the literature on real-world studies of ixazomib in the treatment of RRMM was collected. The quality of the literature was evaluated with the methodological index for non-randomized studies (MINORS) scale. Data such as the effectiveness rate and incidence of adverse events in RRMM patients treated with ixazomib were extracted. The effectiveness indicators included the overall response rate (ORR), very good partial response or better (≥VGPR) rate and median progression-free survival (PFS). The safety indicators included the incidence of adverse events (AEs) and the rate of treatment termination due to AEs, etc. Stata 13.0 software was used for meta-analysis of single proportions, and the occurrence of major adverse events was analyzed by descriptive statistics.
ResultsA total of 12 studies were entered, including 1 006 patients. The quality evaluation results showed that all of the 12 studies were with high quality. The meta-analysis of single proportions showed that ORR of ixazomib in the treatment of RRMM was 65%[95% confidence interval (CI): 58%-72%], ≥VGPR rate was 32% (95%CI: 25%-38%), the median PFS was 21.73 (95%CI: 14.37-29.08) months, the incidence of ≥ grade 3 AEs was 39% (95%CI: 24%-55%), and the incidence of treatment termination due to AEs was 6% (95%CI: 3%-10%). AEs with an incidence of ≥10% included neutropenia, thrombocytopenia, infection, anemia, diarrhea, fatigue, peripheral neuropathy, rashes, and bone pain.
ConclusionIn the real world, the efficacy of ixazomib in the treatment of RRMM is lower than that in clinical trials, but the safety is similar.
Key words:
Multiple myeloma; Proteasome inhibitors; Ixazomib; Efficacy; Safety; Meta-analysis
Contributor Information
Li Yun
Department of Pharmacy, the Second Affiliated Hospital to Nanchang University, Jiangxi Province, Nanchang 330006, China
Li Bingsheng
Department of Chinese Medicine and Health, Nanchang Academy of Health Sciences, Jiangxi Province, Nanchang 330004, China
Yuan Zhen
Department of Health Care, the Second Affiliated Hospital to Nanchang University, Jiangxi Province, Nanchang 330006, China
Liu Bin
Inspection and Testing Center of Nanchang, Jiangxi Province, Nanchang 330006, China
Li Yixiu
Department of Pharmacy, the Second Affiliated Hospital to Nanchang University, Jiangxi Province, Nanchang 330006, China
Ao Jian'gen
Department of Pharmacy, the Second Affiliated Hospital to Nanchang University, Jiangxi Province, Nanchang 330006, China
